牛牛AI助理已提取核心訊息
On April 1, 2024, Karen S Lynch, President and CEO of CVS Health Corp (CVS), completed a stock transaction involving the company's shares. Lynch sold a total of 61,953 shares of common stock at a price of $79.56 per share, resulting in a total transaction value of $4,928,980.68. Following the sale, Lynch's direct holdings in CVS Health Corp amounted to 74,687 shares. The transaction reflects a disposal of shares to cover the payment of exercise price or tax liability, which is a common practice among corporate executives.
On April 1, 2024, Karen S Lynch, President and CEO of CVS Health Corp (CVS), completed a stock transaction involving the company's shares. Lynch sold a total of 61,953 shares of common stock at a price of $79.56 per share, resulting in a total transaction value of $4,928,980.68. Following the sale, Lynch's direct holdings in CVS Health Corp amounted to 74,687 shares. The transaction reflects a disposal of shares to cover the payment of exercise price or tax liability, which is a common practice among corporate executives.
2024年4月1日，CVS Health Corp（CVS）總裁兼首席執行官凱倫·林奇完成了涉及該公司股票的股票交易。林奇以每股79.56美元的價格共出售了61,953股普通股，總交易價值爲4,928,980.68美元。出售後，林奇在CVS Health Corp的直接持股量爲74,687股。該交易反映了出售股票以支付行使價或納稅義務的支付，這是企業高管的慣例。
2024年4月1日，CVS Health Corp（CVS）總裁兼首席執行官凱倫·林奇完成了涉及該公司股票的股票交易。林奇以每股79.56美元的價格共出售了61,953股普通股，總交易價值爲4,928,980.68美元。出售後，林奇在CVS Health Corp的直接持股量爲74,687股。該交易反映了出售股票以支付行使價或納稅義務的支付，這是企業高管的慣例。
有用
沒用